Unicycive Therapeutics (UNCY) News Today $0.53 -0.37 (-40.88%) Closing price 04:00 PM EasternExtended Trading$0.57 +0.04 (+6.75%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Unicycive Shares Slide as FDA Flags Issues Related to Kidney Drug ApplicationJune 10 at 9:23 PM | marketwatch.comUnicycive Therapeutics stock tumbles after FDA flags manufacturing issuesJune 10 at 9:23 PM | investing.comUnicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisJune 10 at 6:00 AM | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short InterestUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 666,100 shares, a decrease of 16.0% from the April 30th total of 793,000 shares. Approximately 0.7% of the company's shares are sold short. Based on an average trading volume of 884,600 shares, the short-interest ratio is presently 0.8 days.June 3, 2025 | marketbeat.comQ2 Earnings Estimate for UNCY Issued By HC WainwrightMay 31, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for UNCY Q2 Earnings?Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for Unicycive Therapeutics in a report released on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.08May 30, 2025 | marketbeat.comQ4 Earnings Estimate for UNCY Issued By HC WainwrightUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth expects that the company wilMay 29, 2025 | marketbeat.comUnicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Unicycive Therapeutics in a research report on Tuesday.May 28, 2025 | marketbeat.comUnicycive Therapeutics to Present at Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comUnicycive Therapeutics Announces Time Change for 2025 Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comQ2 Earnings Forecast for UNCY Issued By Noble FinancialUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Noble Financial issued their Q2 2025 earnings estimates for shares of Unicycive Therapeutics in a note issued to investors on Thursday, May 15th. Noble Financial analyst R. Leboyer expects that the company wiMay 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Acquired by Octagon Capital Advisors LPOctagon Capital Advisors LP raised its position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 16.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 10,000,000 shares of the company's stock after purchasing an additional 1,441,000 sharesMay 15, 2025 | marketbeat.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deUnicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | globenewswire.comAlyeska Investment Group L.P. Trims Stock Holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Alyeska Investment Group L.P. trimmed its holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 22.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,750,000 shares ofMay 9, 2025 | marketbeat.comAnalysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before LongMay 7, 2025 | finance.yahoo.comUnicycive Therapeutics (UNCY) to Release Quarterly Earnings on MondayUnicycive Therapeutics (NASDAQ:UNCY) will be releasing earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-unicycive-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 39.2% in AprilUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the target of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 1,040,000 shares, a decrease of 39.2% from the March 31st total of 1,710,000 shares. Based on an average daily volume of 957,300 shares, the days-to-cover ratio is presently 1.1 days. Currently, 1.1% of the company's stock are sold short.May 1, 2025 | marketbeat.comNantahala Capital Management LLC Increases Holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Nantahala Capital Management LLC lifted its position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 268.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,391,99April 30, 2025 | marketbeat.comSilverarc Capital Management LLC Has $1.98 Million Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Silverarc Capital Management LLC lessened its position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 37.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,486,709 shares of the company's stock after selling 1,513,291April 24, 2025 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Now Covered by Analysts at GuggenheimGuggenheim began coverage on Unicycive Therapeutics in a research report on Monday. They set a "buy" rating and a $6.00 price target for the company.April 23, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Purchased by Vivo Capital LLCVivo Capital LLC boosted its holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 123.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,970,152 shares of the company's stock after buyingApril 23, 2025 | marketbeat.comGuggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy RecommendationApril 22, 2025 | msn.comUnicycive Therapeutics initiated with a Buy at GuggenheimApril 22, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Unicycive Therapeutics (NASDAQ:UNCY)HC Wainwright reiterated a "buy" rating and issued a $7.50 price objective on shares of Unicycive Therapeutics in a report on Friday.April 13, 2025 | marketbeat.comUnicycive presents new patient-level data from Phase 2 study of OLCApril 12, 2025 | markets.businessinsider.comResearch Analysts Offer Predictions for UNCY FY2025 EarningsUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Brookline Capital Management raised their FY2025 EPS estimates for shares of Unicycive Therapeutics in a research note issued to investors on Tuesday, April 1st. Brookline Capital Management analyst K. Raja now expects that thApril 6, 2025 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for UNCYUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - HC Wainwright dropped their Q1 2025 earnings estimates for shares of Unicycive Therapeutics in a report released on Tuesday, April 1st. HC Wainwright analyst E. Arce now anticipates that the company will post earnings of ($0.08) per shareApril 6, 2025 | marketbeat.comBrookline Capital Management Estimates UNCY Q1 EarningsUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities researchers at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a note issued to investors on Tuesday, April 1st. Brookline Capital Management analyst K.April 5, 2025 | marketbeat.comUnicycive Therapeutics price target raised to $7.50 from $4 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comNoble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)April 2, 2025 | markets.businessinsider.comHC Wainwright Increases Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $7.50HC Wainwright increased their price target on Unicycive Therapeutics from $4.00 to $7.50 and gave the company a "buy" rating in a research report on Tuesday.April 2, 2025 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPSUnicycive Therapeutics (NASDAQ:UNCY - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13).April 1, 2025 | marketbeat.comUnicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comUnicycive Therapeutics reports FY24 EPS (56c), consensus (51c)April 1, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comUnicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on ThursdayUnicycive Therapeutics (NASDAQ:UNCY) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest UpdateUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,400,000 shares, a growth of 76.1% from the February 13th total of 795,200 shares. Approximately 1.6% of the company's shares are short sold. Based on an average daily trading volume, of 1,090,000 shares, the short-interest ratio is presently 1.3 days.March 15, 2025 | marketbeat.comUnicycive to present patient reported outcomes data from UNI-OLC-201 studyMarch 13, 2025 | markets.businessinsider.comUnicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of HyperphosphatemiaMarch 13, 2025 | globenewswire.comUnicycive Therapeutics (NASDAQ:UNCY) Trading Down 2% - Should You Sell?Unicycive Therapeutics (NASDAQ:UNCY) Shares Down 2% - Here's What HappenedMarch 8, 2025 | marketbeat.comUnicycive Therapeutics’ OLC shows synergy with tenapanor in published studyFebruary 21, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360February 20, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Large Growth in Short InterestUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,240,000 shares, a growth of 25.4% from the December 31st total of 989,200 shares. Currently, 1.4% of the company's shares are sold short. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is currently 0.8 days.January 31, 2025 | marketbeat.comBuy Rating for Unicycive Therapeutics Driven by Promising OLC Treatment and Reduced Pill BurdenJanuary 29, 2025 | markets.businessinsider.comUnicycive Therapeutics' (UNCY) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of Unicycive Therapeutics in a research note on Wednesday.January 29, 2025 | marketbeat.comUnicycive highlights challenges in phosphate managementJanuary 28, 2025 | msn.comUnicycive announces publication of patient perspectives on phosphate managementJanuary 28, 2025 | markets.businessinsider.comHere's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn SituationJanuary 28, 2025 | finance.yahoo.comUnicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological ScienceJanuary 28, 2025 | globenewswire.com Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address UNCY Media Mentions By Week UNCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UNCY News Sentiment▼1.450.68▲Average Medical News Sentiment UNCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UNCY Articles This Week▼31▲UNCY Articles Average Week Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aura Biosciences News Entrada Therapeutics News Alpha Teknova News Olema Pharmaceuticals News Compass Therapeutics News Rocket Pharmaceuticals News Heron Therapeutics News Aurora Cannabis News Terns Pharmaceuticals News Cidara Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UNCY) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UNCY Stock Free UNCY Stock Alerts